QED Investors Announces Acquisition of Lingua Franca Search
Retained search firm allows QED to support portfolio companies with their most crucial hires ALEXANDRIA,…
News
University of Phoenix Lead Cybersecurity Faculty Stephanie Benoit-Kurtz to Keynote Women in IT Special Event
Specialty event brings together women in technology to discuss future of industry PHOENIX–(BUSINESS WIRE)–University of…
Why developers hold the key to cloud security
Josh Stella explains why developer-first security is the future in the cloud BOSTON–(BUSINESS WIRE)–#API–In a…
Acasti Announces Court Dismissal of Stockholder Litigation
LAVAL, Québec, Sept. 30, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”)…
Arvinas Gives Back to Local Greater New Haven Community
NEW HAVEN, Conn., Sept. 30, 2022 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage…
Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End
WARMINSTER, Pa., Sept. 30, 2022 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage…
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
New ex vivo data demonstrates protection against cyclophosphamide-induced damage to hair follicles and their stem…
OpGen Announces $3.38 Million Registered Direct Offering
ROCKVILLE, Md., Sept. 30, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the…
Panbela Announces Pricing of Approximately $6 Million Public Offering
MINNEAPOLIS, Sept. 30, 2022 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela” or the…
Mersana Therapeutics Announces Launch of Oncology FACETS, a Resource for Healthcare Providers to Advance Knowledge in Gynecologic Malignancies
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage…
Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma
Preclinical results demonstrated that topotecan treatment enhanced VCN-01 oncolytic activity against retinoblastoma ROCKVILLE, Md., Sept….
Eyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr.
NEW YORK, Sept. 30, 2022 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic…
scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting
Presentations highlight the significant potential clinical benefits of managing congestion in patients with heart failure…
Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint
Company remains on track to resubmit new drug application (NDA) for OCA in its lead…
Medicenna Extends Period to Exercise Certain Warrants
TORONTO and HOUSTON, Sept. 30, 2022 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”)…
Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced that the…
Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting
WALTHAM, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global…
SciSparc Completes the Acquisition of Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
Wellution™ offers dozens of products including natural supplements, creams, gels and hemp-based products on Amazon.com…
Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer
ZUG, Switzerland, Sept. 30, 2022 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing…
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
Initiation of Phase 1/2a Clinical Trial Expected to Occur in Q4 2022 CAMBRIDGE, Mass., Sept….